1921
  1. Home
  2. The American Journal of Tropical Medicine and Hygiene
  3. Volume 77, Issue 6_Suppl
  4. Article
Volume 77, Issue 6_Suppl
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645
Download

Abstract

In 2004, the Institute of Medicine concluded that a global high-level subsidy was the best way to make effective antimalarial drugs—currently, artemisinin-combination therapies (ACTs)—widely available at affordable prices and at the same time substantially delay the emergence and spread of artemisinin-resistant strains of falciparum malaria. The subsidy would be available to manufacturers of all ACTs meeting pre-specified efficacy, safety, and quality criteria. Buyers would pay very low prices, allowing drugs to flow through existing channels, with the aim of reaching consumers at a similar price to chloroquine, the most frequently used (although no longer effective) malaria drug. Unsubsidized artemisinin monotherapies would be more expensive than subsidized ACTs (co-formulations), thereby largely eliminating their use through market forces. Conditions favoring the emergence of artemisinin-resistant malaria would be greatly reduced. The global high-level subsidy is a powerful idea that is moving from economic concept to pragmatic reality.

Copyright 2007 The American Society of Tropical Medicine
Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.2007.77.219
2007-12-01
2020-10-27

  • From This Site

    /content/journals/10.4269/ajtmh.2007.77.219
    dcterms_title,dcterms_subject,pub_keyword
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/14761645/77/6_Suppl/0770219.html?itemId=/content/journals/10.4269/ajtmh.2007.77.219&mimeType=html&fmt=ahah

References

  1. Harinasuta T, Suntharasamai P, Viravan C, 1965. Chloroquine-resistant falciparum malaria in Thailand. Lancet 7414 : 657–660.
     [Google Scholar]
  2. Talisuna AO, Bloland P, D’Alessandro U, 2004. History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev 17 : 235–254.
     [Google Scholar]
  3. Snow RW, Trape JF, Marsh K, 2001. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol 17 : 593–597.
     [Google Scholar]
  4. Korenromp EL, Williams BG, Gouws E, Dye C, Snow RW, 2003. Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infect Dis 3 : 349–358.
     [Google Scholar]
  5. White NJ, 1999. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 41 : 301–308.
     [Google Scholar]
  6. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, Kokwaro G, Ouma J, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruebush TK, Danis M, Greenwood BM, Anderson RM, Olliaro P, 1999. Averting a malaria disaster. Lancet 353 : 1965–1967.
     [Google Scholar]
  7. Jack A, 2006. Up to 10m malaria tablets ‘may be destroyed’. Financial Times. July 24: Europe 4.
  8. Arrow KJ, Panosian CB, Gelband H, 2004. Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance, Washington, DC: National Academy Press.
  9. Laxminarayan R, Over M, Smith DL, 2006. Will a subsidy of new antimalarials delay the emergence of resistance and save lives? Health Aff 25: 325–336.
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2007.77.219
Loading
  • Received : 29 Dec 2006
  • Accepted : 05 Mar 2007

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error